Scarica l'app Stockscreener
1.27
0.78%
-0.01
Dopo l'orario di chiusura:
1.28
0.01
+0.79%
Precedente Chiudi:
$1.28
Aprire:
$1.28
Volume 24 ore:
112.26K
Relative Volume:
0.23
Capitalizzazione di mercato:
$3.19M
Reddito:
-
Utile/perdita netta:
$-8.26M
Rapporto P/E:
-0.0237
EPS:
-53.609
Flusso di cassa netto:
$-12.17M
1 W Prestazione:
-3.79%
1M Prestazione:
-3.05%
6M Prestazione:
-90.39%
1 anno Prestazione:
-96.19%
Intervallo 1D:
$1.23
$1.29
Intervallo di 1 settimana:
$1.20
$1.40
Portata 52W:
$1.10
$43.69
Gri Bio Inc Stock (GRI) Company Profile
Nome
Gri Bio Inc
Settore
Industria
Telefono
(619) 400-1171
Indirizzo
2223 AVENIDA DE LA PLAYA, LA JOLLA
Confronta GRI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.27 | 3.19M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-09 | Iniziato | H.C. Wainwright | Buy |
Gri Bio Inc Borsa (GRI) Ultime notizie
Q2 Earnings Estimate for GRI Bio Issued By HC Wainwright - Defense World
Kalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare Space - Kalkine Media
GRI Bio (NASDAQ:GRI) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for GRI Bio (NASDAQ:GRI) - Defense World
GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Given “Buy” Rating at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Earns Buy Rating from HC Wainwright - Defense World
GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock By Investing.com - Investing.com India
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock - Investing.com
GRI Stock Maintains Buy Rating and $10 Price Target | GRI Stock News - GuruFocus
GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus
GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World
GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria
GRI Bio Expands Share Offering Agreement - TipRanks
GRI Bio expands at-the-market offering capacity - Investing.com
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus
GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus
GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com
GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India
GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - The Manila Times
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan
GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India
GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus
GRI Bio reports positive early trial data for IPF treatment - Investing.com
GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times
GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq
GRI Bio, Inc. SEC 10-Q Report - TradingView
GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire
GRI Bio reports positive interim biomarker data in IPF study By Investing.com - Investing.com Nigeria
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend - GlobeNewswire
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621 - marketscreener.com
GRI Bio reports positive interim biomarker data in IPF study - Investing.com
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis - marketscreener.com
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times
GRI Bio (GRI) to Release Earnings on Friday - Defense World
GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World
Gri Bio Inc Azioni (GRI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):